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A B S T R A C T
Background: Heroin overdose is a major cause of premature death.
Naloxone is an opioid antagonist that is effective for the reversal of
heroin overdose in emergency situations and can be used by non-
medical responders. Objective: Our aim was to assess the cost-effective-
ness of distributing naloxone to adults at risk of heroin overdose for use
by nonmedical responders compared with no naloxone distribution in a
European healthcare setting (United Kingdom). Methods: A Markov
model with an integrated decision tree was developed based on an
existing model, using UK data where available. We evaluated an
intramuscular naloxone distribution reaching 30% of heroin users. Costs
and effects were evaluated over a lifetime and discounted at 3.5%. The
results were assessed using deterministic and probabilistic sensitivity
analyses. Results: The model estimated that distribution of intramus-
cular naloxone, would decrease overdose deaths by around 6.6%. In a
population of 200,000 heroin users this equates to the prevention of
2,500 premature deaths at an incremental cost per quality-adjusted life
year (QALY) gained of £899. The sensitivity analyses conﬁrmed the
robustness of the results. Conclusions: Our evaluation suggests that the
distribution of take-home naloxone decreased overdose deaths by
around 6.6% and was cost-effective with an incremental cost per QALY
gained well below a £20,000 willingness-to-pay threshold set by UK
decision-makers. The model code has been made available to aid future
research. Further study is warranted on the impact of different
formulations of naloxone on cost-effectiveness and the impact take-
home naloxone has on the wider society.
Keywords: cost-effectiveness, death, drug overdose, economic model,
heroin addiction, naloxone, preventative measures, quality-adjusted
life-years.
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Introduction
Heroin use carries a high risk of respiratory depression and over-
dose death, which accounts for substantial mortality in Europe,
and has recently increased in some regions in Europe [1,2].
Naloxone, an opioid antagonist, has been shown to decrease
overdose-related mortality when used by nonmedical responders
in emergency situations, in combination with training and educa-
tion [3–6]. European drug agencies [7] and the World Health
Organization [8] recommend that take-home naloxone be more
widely available. Preﬁlled formulations of naloxone for intramus-
cular administration have been the predominant form used in
take-home naloxone programs across Europe [7,9]; an intranasal
form has, however, been used in recent programs in Norway and
Denmark (preﬁlled syringe with nasal adaptor kit) [10,11].
To date, no studies have assessed the cost-effective of take-
home naloxone in Europe. Two studies in the United States
[12,13], one of which was later adapted to Russia [14], modeled
the costs and beneﬁts of distributing intramuscular naloxone to
heroin users for use by nonmedical responders. In both cases,
naloxone was considered to be robustly cost-effective. Given the
recent rise of drug-related mortality in some countries across
Europe and the call for the increase in availability of take-home
naloxone programs, it will be critical for decision makers to
understand the pharmacoeconomic implications of implement-
ing new programs or expanding existing ones.
There is a need for an economic assessment of take-home
naloxone in the European setting from a public health system
perspective. The main objective of this study was to replicate the
US economic model developed by Cofﬁn and Sullivan [12] and adapt
it to the United Kingdom to assess the cost-effectiveness of distrib-
uting naloxone to adults at risk of heroin overdose for use by
nonmedical responders (i.e., heroin users, family, friends, and carers).
We chose the United Kingdom because of its high and increasing
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heroin-related mortality rate [1,15], the introduction of new govern-
ment regulations in 2015 making naloxone exempt from prescrip-
tion-only medicine requirements [16], and policy imperatives aimed
at widening use [17]. Because current health economic models in the
area are not widely available, a secondary objective of this study was
to make a version of our model publicly available in R language,
version 3.3.2 (R Foundation for Statistical Computing, Vienna, Aus-
tria) [18]. This version is available as a supplementary ﬁle with an
associated “readme” instruction ﬁle. It allows researchers to inves-
tigate further the costs and beneﬁts of interventions aimed at
reducing overdose deaths and also aids health care decision makers
with resource allocation decisions by presenting fully transparent
and adaptable calculations.
Methods
Model Structure
A Markov model [19] with an integrated decision tree was
developed to estimate the costs and outcomes of distributing
take-home naloxone to adults at risk of heroin overdose. The
model was a replication of the Cofﬁn and Sullivan model [12] and
adaptations were made to both structure and content to make it
relevant for the UK health care system. The model had a lifetime
horizon (default value set at 64 years), a health care perspective,
1-year cycles and it included standard background mortality [20].
The Markov model tracked heroin users through four health
states (Fig. 1). Heroin users were to enter the model in “heroin
use” and could discontinue heroin use, resume heroin use, or die
for other reasons (all-cause death). Heroin users could also have
an overdose (fatal or nonfatal), which was modeled separately
using a decision tree (Fig. 2). The decision tree produces three
cycles of overdose, with the ﬁnal cycle for the third and all
subsequent overdose events. The decision tree models the
potential pathway of a patient through an overdose event for
intramuscular naloxone distribution versus no naloxone distri-
bution. An overdose could be witnessed or not witnessed, and of
those witnessed, naloxone may or may not be administered
when available. Furthermore, in overdoses that are witnessed,
an ambulance may or may not be called. At the terminus of each
arm, the patient may either live or die. The probabilities at each
stage differ depending on whether the overdose is witnessed,
naloxone is available, naloxone is used, and whether an ambu-
lance is called.
First, a replication of the Cofﬁn and Sullivan model was
developed using the same structure and parameter inputs for
all clinical and cost variables as published in the original article
[12]. The accuracy of the model was assessed by comparing the
clinical and cost-effectiveness outcomes with those provided by
Cofﬁn and Sullivan (personal communication, June, 2016). We
were conﬁdent that we had replicated the original model as
closely as possible with differences in incremental costs, quality-
adjusted life-years (QALYs) and cost-effectiveness ratio being no
more than $5, 0.01, and $23, respectively. This variance resulted
from rounding effects and uncertainty regarding inputs not
reported or referenced in the Cofﬁn and Sullivan article, for
example, standard background mortality rates.
Second, the replicated model was adapted to the UK health
care system, which included structure and content changes.
A targeted literature review was conducted to identify UK-speciﬁc
input parameters, when available. Key terms were used to search
MEDLINE and online search engines (search terms included
heroin, opioid, drug-related mortality, overdose, and naloxone).
No date limit was applied to the searches. The baseline model
was adjusted to begin at 22 years, which reﬂects the average age
of onset of heroin use in Europe [21], and age-speciﬁc background
mortality for the United Kingdom was used [22]. The input
parameters and ranges are presented in Table 1, with detailed
rationale for parameter selection given in Appendix Table 1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2018.07.014. The model was built in Microsoft Excel 2016 and
subsequently reproduced in R version 3.3.2 [18] and validated
against the Excel version.
Markov Model Transitions
Annual transition probabilities outlined in the Cofﬁn and Sullivan
model were based on epidemiological evidence derived from
North America, Australia, and Europe [12]. It was assumed that
these estimates were relevant for the United Kingdom. The
estimates are based on evidence demonstrating that 50% of users
relapse over 5 years resulting in a medium duration of heroin use
of 15 years, 33% to 70% of users overdose over a lifetime, and the
principal risk factor for overdose is previous overdose and there-
fore risk increases with each overdose [12].
Decision-Tree Parameters
Decision-tree input parameters were adapted to align with the
availability and structure of UK health care services and were
sourced from UK studies when available. The proportion of
heroin users reached by the naloxone take-home program was
assumed to be 30%. This was based on the target coverage for the
Scottish naloxone take-home program aiming to reach one-third
of injecting heroin users [23]. The proportion of witnessed over-
doses was assumed to be 85%, on the basis of a UK study
demonstrating that 85% of heroin users in treatment had a
Fig. 1 – Markov model of heroin use, discontinuation
overdose, and death. Adapted from Cofﬁn and Sullivan [12].
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witnessed overdose [24]. The Cofﬁn and Sullivan model outlined
one estimate for “the proportion in possession of naloxone at an
overdose who attempt to use it to attempt reversal” [12]. Never-
theless, this estimate is made up of the proportion of witnessed
overdoses when naloxone is available (i.e., has not been lost or is
not with the victim at the time of the overdose) and the
proportion of witnesses with naloxone who attempt to use it.
The model was adapted to include both these input parameters
independently to improve model accuracy. The model assumed
that 75% of users would have their naloxone kit available at the
time of an overdose and in 90% of cases there would be an
attempt to use it. These were based on information from several
UK studies and the Scottish and Welsh take-home programs
[24–29]. As in the original Cofﬁn and Sullivan model [12], the
same value was used in the sensitivity analysis for the social
network modiﬁer, which accounted for variations in the like-
lihood that users would take heroin in the presence of others
who had been reached by the naloxone take-home program.
The likelihood of calling an ambulance and being taken to
hospital was structured in a slightly different way compared with
the original model aligning with data availability and UK policy
guidelines on transport to hospital after an overdose. The likelihood
of calling an ambulance is based on a survey from the Welsh
naloxone take-home program [29]. The likelihood of being taken to
accident and emergency was assumed to be 100% following UK
guidelines stating all patients suffering an opioid overdose should
be transported to further care [30]. Established estimates of over-
dose mortality, recurrent overdoses, and the increase in survival
after the use of naloxone or calling an ambulance were based on
estimates used in the Cofﬁn and Sullivan model [12,14] and UK
estimates [9,23,27,31] when available.
Costs
Naloxone costs were based on the British National Formulary list
price for Prenoxad® (Martindale Pharmaceuticals Ltd., Bucking-
hamshire, United Kingdom), an intramuscular injection (1 mg/ml,
2 ml preﬁlled syringe), which is licensed for use in the commun-
ity [32]. Naloxone costs were incurred after each overdose when
naloxone was administered biannually among active heroin
users to account for naloxone going out of date (shelf life of
Prenoxad is 3 years) and for losses. Distribution costs of £8 were
assumed per naloxone prescription, on the basis of those esti-
mated by Cofﬁn and Sullivan [12]. Naloxone take-home programs
included distribution of naloxone in combination with training
users, and their family, friends, and carers, on how to administer
the product in the event of an overdose [31,33]. Training costs
were not included in the original Cofﬁn and Sullivan model [12].
Fig. 2 – Decision tree for the overdose health state. Adapted from Cofﬁn and Sullivan [12].
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Guidance suggests that training could be run on a one-to-one
basis or in a small group. Costs were estimated at £124 on the
basis of a per-care contact with the drug service [34] and applied
for ﬁrst-time administration of naloxone. Costs for an ambulance
callout and visit to accident and emergency were sourced from
National Health Service reference costs [35]. Costs are presented
in UK pounds, using 2016 as the costing year and discounted at
3.5%, in accordance with UK guidance [36].
Outcomes
Outcomes were expressed in terms of clinical outcomes (number
of overdoses and overdose deaths) and cost-effectiveness out-
comes (cost per QALY, discounted at 3.5% per annum) [36].
Absolute utility values for a heroin user not in treatment,
together with a relative increase in utility for those in recovery,
were assumed to be the same as those in the Cofﬁn and Sullivan
model [12].
Sensitivity Analysis
Deterministic and probabilistic sensitivity analyses were carried
out to assess the robustness of the model. Univariate analysis,
whereby input values are individually varied to plausible upper
and lower bounds while remaining values retained their baseline,
was undertaken for all input parameters. Selected results were
plotted in a tornado diagram and, in addition, were documented
in a tabular format.
Table 1 – Naloxone distribution model parameters.
Input name Base case (range) Source
Markov model annual transition parameters for UK adaptations
Heroin use to nonoverdose death (in excess of background mortality) 0.0075 (0.0025–0.0125) [12]
Heroin use to overdose [12]
First overdose 0.09 (0.02–0.12)
Second overdose 0.22 (0.05–0.30)
Subsequent overdoses 0.34 (0.27–0.60)
Annual relative reduction in risk for ﬁrst overdose 0.933 (0.900–1.000) [12]
Heroin use to discontinuation of heroin use 0.06 (0.01–0.10) [12]
Discontinuation of heroin use to heroin use 0.070 (0.056–0.084) [12]
Annual relative reduction in risk for relapse 0.933 (0.900–1.000) [12]
Overdose to discontinuation of heroin use 0.062 (0.028–0.113) [12]
Decision-tree parameters (proportions) used in the UK adaptations
Joint probability that distributed naloxone is used each year (calculated) 0.17 Calculated
Proportion of heroin users prescribed naloxone 0.30 (0.05–0.60) [12,23]
Proportion of witnessed overdoses 0.85 (0.32–0.94) [12,24,49]
Proportion of witnessed overdoses when naloxone is available (i.e., has not been
lost or not with the victim at the time of the overdose)
0.75 (0.40–0.85) Assumption based on
References [25–28]
Proportion of witnesses with naloxone who attempt to use it 0.90 (0.77–0.99) Assumption based on
References [24,27,29]
Social network modiﬁer 1.0 (0.5–1.5) [12]
Proportion who call an ambulance
Proportion who call an ambulance (no naloxone use) 0.60 (0.30–0.80) [29]
Proportion who call an ambulance (no naloxone use) and then go to accident
and emergency
1.0 (0.50–1.0) [30]
Proportion who call an ambulance after naloxone use 0.85 (0.55–0.95) [25]
Proportion who call an ambulance after naloxone use and then go to accident
and emergency
1.0 (0.50–1.0) [30]
Proportion who survive overdose
Proportion who survive an unwitnessed overdose 0.90 (0.80–0.94) [14]
Reduction in survival for second overdose 0.015 (0.000–0.020) [12]
Reduction in survival for subsequent overdoses 0.015 (0.000–0.020) [12]
Proportion who survived a witnessed overdose (no naloxone or ambulance) 0.918 (0.800–0.940) [12]
Relative increase in survival during a witnessed overdose when an ambulance
was called (no naloxone)
1.013 (0.980–1.035) Assumption based on
Reference [23]
Relative increase in survival during a witnessed overdose with naloxone 1.067 (1.035–1.089) Assumption based on
References [9,12,27,31]
UK model costs
Intramuscular naloxone (1 mg/ml, 2 ml preﬁlled syringe of Prenoxad®) £15.30 is the price for
one
[32]
Distribution £8.50 [12]
Training costs for users, family, and friends £124 per kit for ﬁrst-
time administration
[34]
Ambulance £233 [35]
Accident and emergency visit £278 [35]
Utility values
Heroin user 0.80 (0.73–0.90) [12]
Relative increase in utility for heroin user in recovery 1.07 (1.00–1.13) [12]
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Probabilistic sensitivity analysis was also undertaken by
randomly drawing values from a distribution around each of
the inputs during 10,000 simulations. Distributions were beta
distribution for proportions and transition rates, gamma for costs
and utility decrements, and lognormal for utility rates. The
results of these simulations were used to form a scatterplot of
incremental effectiveness against incremental costs of naloxone
distribution versus no naloxone distribution. In addition,
the results from each of these simulations were used to
calculate incremental net beneﬁts and from these a cost-
effectiveness acceptability curve demonstrating the probability
of cost-effectiveness at different willingness-to-pay thresholds
was created.
Scenario Analysis
A number of scenario analyses were carried out. First, the impact
of increasing the costs of naloxone distribution was assessed.
This included increasing the price, the distribution costs, and the
training costs. Second, the impact of adding societal costs to the
model was assessed, that is, making the assumption that heroin
users are a net cost to society. We assessed the impact of
Table 2 – Base case, sensitivity analysis, and scenario analysis results.
Input name Lifetime
overdose
deaths
averted (%)
Incremental cost
of naloxone
distribution (£)
Incremental
QALY of
naloxone
distribution
ICER of
naloxone
distribution
(£)
Base case 6.6 146 0.163 899
Sensitivity analyses
Proportion of heroin users prescribed naloxone
increased from 30% to 60%
13.6 295 0.331 891
Proportion of heroin users prescribed naloxone
decreased from 30% to 5%
1.1 24 0.027 905
Social network modiﬁer increased from 1.0 to 1.5 10.1 167 0.246 679
Social network modiﬁer decreased from 1.0 to 0.5 3.3 125 0.081 1,557
Proportion of witnessed overdoses increased from 85%
to 94%
7.6 152 0.182 835
Proportion of witnessed overdoses decreased from
85% to 32%
2.1 118 0.057 2,047
Relative increase in survival when naloxone available
decreased from 1.067 to 1.035
3.0 142 0.074 1,917
Proportion of witnesses with naloxone who attempt to
use it increased from 90% to 99%
7.3 150 0.179 839
Proportion of witnesses with naloxone who attempt to
use it reduced from 90% to 77%
5.7 140 0.139 1,010
Proportion of witnessed overdoses in which naloxone
is available increased from 75% to 85%
7.5 152 0.185 821
Proportion of witnessed overdoses when naloxone is
available reduced from 75% to 40%
3.5 127 0.086 1,475
No quality-of-life improvement for heroin user in
recovery
6.6 146 0.156 935
Naloxone distribution costs increased 10-fold (from
£8.50 to £85.00)
6.6 388 0.163 2,388
Rate of ﬁrst overdose increased from 9% to 12% 6.6 152 0.197 772
Rate of ﬁrst overdose reduced from 9% to 2% 6.7 126 0.046 2,716
Scenario analyses
Naloxone price increased 10-fold (from £15.30 to
£153.00)
6.6 582 0.163 3,580
Naloxone price increased 10-fold and distribution and
training costs doubled
6.6 645 0.163 3,965
Addition of an annual cost to society of a heroin user
and discontinued heroin user: criminal justice costs
only
6.6 2,621 0.163 16,121
Addition of an annual cost to society of a heroin user
and discontinued heroin user: criminal justice and
victim costs
6.6 8,321 0.163 51,172
Multivariate scenario: lower thresholds for witnessed,
naloxone available, naloxone used, efﬁcacy and
price of naloxone doubled
0.4 155 0.012 12,925
Multivariate scenario: higher thresholds for
witnessed, naloxone available, naloxone used,
efﬁcacy and price of naloxone at base case
13.2 168 0.315 534
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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applying a societal cost to all heroin users and discontinued
heroin users in the model. The societal cost applied included
criminal justice and victim costs. Costs used were those reported
by a UK health technology assessment of methadone and
buprenorphine and inﬂated to 2016 prices. Original costs reported
by Connock et al. [37] are provided in parentheses. For
heroin users, criminal justice and victim costs were £13,592
(£8,397) and £14,395 (£8,893), respectively, and for discontinued
heroin users, these were £11,390 (£7,037) and £49,900 (£30,827),
respectively. Third, multivariate deterministic scenarios
were developed using combined plausible upper and lower
bounds for the following parameters: overdose witness rates,
cost and efﬁcacy of naloxone, and rates of carrying and use of
naloxone.
Results
Clinical and Economic Outcomes
The economic model estimated that a distribution of take-home
naloxone reaching 30% of heroin users would prevent 6.6% of
overdose deaths at an incremental cost-effectiveness ratio of
£899/QALY gained over a lifetime (Table 2).
In a population of 200,000 heroin users with no naloxone
distribution, the model estimated that there would be 385,007
overdoses, of which 9.8% would result in death (37,688). Although
a 30% distribution of naloxone to adults at risk of heroin overdose
for use by nonmedical responders would increase the number of
overdoses by 2.7% (to 395,416) because of the increase in
survival of heroin users at risk of a subsequent overdose, it
would result in a decrease in the number of overdose deaths by
2,500 (to 35,188).
Results of the probabilistic analysis are presented in the next
section. In terms of conﬁdence intervals (CIs) around the
observed values, a 30% distribution of intramuscular naloxone
to heroin users would increase lifetime QALYs by 0.164 (95% CI,
0.021–0.514) and costs by £156 (95% CI, £33–£365) for an incre-
mental cost per QALY gained of £952 (95% CI, £431–£3,330).
Sensitivity Analysis
Cost effectiveness (Fig. 3; Table 2) was somewhat sensitive to rate
of ﬁrst overdose, proportion of witnessed overdoses, the efﬁcacy
of naloxone (in terms of impact on survival), the proportion of
witnessed overdoses when naloxone was available, and the
social network modiﬁer (which reﬂects the likelihood that users
would take heroin in the presence of others who had been
reached by the naloxone take-home program). Cost-effectiveness
was relatively insensitive to the remaining parameters. Incre-
mental cost per QALY gained did not exceed more than £3,000 in
any of the univariate analyses. Those that increased the incre-
mental cost per QALY gained to more than £2,000 included
reducing the rate of ﬁrst overdose from 9% to 2%, increasing
Fig. 3 – One-way sensitivity analysis of the cost-effectiveness of naloxone distribution. A&E, accident and emergency; IM,
intramuscular; NX, naloxone; QALY, quality-adjusted life-year.
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the distribution costs of naloxone 10-fold, and decreasing the
proportion of witnessed overdoses from 85% to 32%.
In addition, a number of univariate analyses demonstrated
further increases, over the base case, in lifetime overdose deaths
averted. Analyses in which the percentage of lifetime overdose
deaths averted exceeded 7% included increasing 1) the proportion
of heroin users prescribed naloxone from 30% to 60%, 2) the social
network modiﬁer from 1.0 to 1.5, 3) the proportion of witnessed
overdoses from 85% to 94%, 4) the proportion of witnessed
overdoses when naloxone is available from 75% to 85%, and
5) the proportion of witnesses with naloxone who attempt to use
it from 90% to 99%.
The cost-effectiveness acceptability plane (Fig. 4A) and the
cost-effectiveness acceptability curve (Fig. 4B) demonstrate the
high probability (99.8%) that naloxone distribution is cost-effective
compared with no naloxone distribution at a cost per QALY
threshold of less than £20,000.
Scenario Analysis
The scenario analysis results are presented in Table 2. Increasing
the price of intramuscular naloxone 10-fold and doubling the
distribution and training costs increased the incremental cost-
effectiveness ratio to £3,965/QALY gained. The addition of annual
societal costs of a heroin user and discontinued heroin user
increased the incremental cost-effectiveness ratio to £16,121/
QALY gained when only criminal justice costs were included
and to £51,172/QALY gained when both criminal justice and
victim costs were included. The multivariate deterministic
scenario analysis for lower parameter bounds, using a health
care perspective and not including societal costs (cost of nalox-
one was doubled and the likelihood of an overdose being
witnessed, naloxone being available and used, and the efﬁcacy
of naloxone was set to lower values), generated an incremental
cost-effectiveness ratio of £12,925/QALY gained with an
estimated 0.4% of overdose deaths being avoided.
Discussion
The main objective of this study was to replicate and adapt an
economic model developed by Cofﬁn and Sullivan [12], and use
epidemiological data in the absence of clinical trials, to assess the
cost-effectiveness of distributing intramuscular naloxone to
adults at risk of heroin overdose for use by nonmedical respond-
ers compared with no naloxone distribution in a European
setting. A naloxone take-home program in a European market,
in this case the United Kingdom, targeted at 30% of heroin users,
was shown to be highly cost-effective. The sensitivity analysis
conﬁrmed the robustness of the results. These results are in line
with the cost-utility analyses conducted for the United States
[12,13] and Russia [14], where the incremental cost-effectiveness
ratio of naloxone distribution was US $438 [12], US $323 [13], and
US $94/QALY gained [14] compared with no naloxone distribu-
tion. The small difference in cost-effectiveness relative to the
present study can be accounted for by differences both in study
design and in health care systems. In terms of study design, there
were differences in parameter estimates and costs included; for
example, the US and Russian studies did not include the cost of
training heroin users and their family, friends, and carers on
naloxone use. In addition, structural adaptations were made to
the current model to improve accuracy. In terms of health care
systems, there were differences in the assumed availability of
services. For example, in the Russian study, it was assumed that
emergency services were called only in a minority of cases and
that they had no impact on survival. This was in contrast to the
present study, which assumed a high rate of contact with
emergency services, which had a consequent positive impact
on survival.
In terms of clinical outcomes, the model predicted that
naloxone distribution would decrease overdose deaths by about
6.6%. In a population of 200,000 heroin users, this equates to
saving 2,500 lives over a lifetime. The sensitivity analyses
demonstrated that, among other variables, increasing the distri-
bution of take-home naloxone to heroin users and increasing the
use and availability of naloxone at the time of a witnessed
overdose would improve these clinical outcomes further. This
has important policy implications. The analysis suggests that the
implementation of new take-home naloxone programs or
expanding existing ones will have a measurable positive impact
on lives saved. It also suggests that focusing on those aspects of
the program that may lead to an increased availability or use of
naloxone at the time of an overdose death, through for example
training or different types of naloxone administration, could
further increase the clinical beneﬁts.
The clinical outcomes estimated in our model are very
conservative compared with reductions in overdose deaths seen
in the Scottish national naloxone program that started in 2011.
An early evaluation of the effectiveness of the program, the ﬁrst
assessment of a naloxone program at the population level,
demonstrated a 36% reduction in the proportion of heroin-related
overdose deaths that occurred in the 4 weeks after release from
prison [5]. This study estimated that the cost per QALY gained
would range from £560 to £1940; nevertheless, only prescription
costs were included in the analysis. The utility of a heroin user
was assumed to be 0.7 with life-years gained by overdose-related
death prevention of 10 years.
Fig. 4 – (A) Cost-effectiveness acceptability plane and
(B) CEAC for IM naloxone compared with no naloxone
distribution. CEAC, cost-effectiveness acceptability curve;
IM, intramuscular; PSA, probabilistic sensitivity analysis;
QALY, quality-adjusted life-year; WTP, willingness to pay.
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Evidence from the Welsh national naloxone program and pilot
programs in England suggests that 95% to 100% of heroin users
who had overdoses that were witnessed, and when naloxone was
available and administered, survived [9,27,31]. These evaluations
were not designed to assess the reduction in overdose mortality
resulting from naloxone distribution and are limited by small
sample sizes. Nevertheless, an analysis conducted by the World
Health Organization of 20 global take-home naloxone programs
found a mortality rate in witnessed overdoses of 1.0% (0.83%–
1.21%) and although there were no comparators in these studies,
the report outlined that the mortality rate after overdoses has
previously been estimated at 2% to 4%. Despite classifying the
quality of evidence on the effectiveness of take-home naloxone as
“very low,” the World Health Organization issued a strong recom-
mendation to provide access to and training on administration of
naloxone to people likely to witness a heroin overdose [8].
Only the intramuscular route of administration of naloxone is
available in the United Kingdom currently. Introduction of an intra-
nasal formulation would have added value over an intramuscular
route of administration. Similar efﬁcacy, in terms of time to reversal
of overdose, has been demonstrated [38–40]. There is, however, no
risk of needle-stick injury and subsequent risk of infection from
blood-borne pathogens with the intranasal route of administration
[41], a particular concern for nonmedical responders given the high
rate of HIV and hepatitis B or C in heroin users [42,43]. It is also easier
to use, requires less training, and the nose is often readily available
[41]. Such beneﬁts may increase distribution and the likelihood of
use during an overdose. Furthermore, a recent study suggested that
the proportion of injecting drug users prescribed intramuscular
naloxone who carry it with them could be as low as 5% [44].
Injecting drug users have stated a preference for the intranasal
mode of administration [45] and therefore availability of such a
formulation may lead to higher carriage rates.
The second objective of this study was to enable further
research on the costs and beneﬁts of interventions aimed at
reducing heroin-related overdose deaths. There has been a recent
debate emphasizing the need to improve transparency in deci-
sion making. We have therefore made our model available online
in R format to ensure transparency and help facilitate future
research and policy recommendations [46].
This study has several limitations. First, the model uses data
based on epidemiological studies in the absence of randomized
controlled trials and, when data were not available for the United
Kingdom, input parameters were drawn from the original Cofﬁn
and Sullivan model that contained predominantly North Amer-
ican data, with supporting evidence from Australia and Europe
[12]. This was accounted for by carrying out extensive sensitivity
analyses to test the robustness of the results.
Second, there are potential beneﬁts of training drug users on
the administration of naloxone and guidelines to follow if they
witness an overdose which are not included in this analysis that
could potentially lead to improved cost-effectiveness estimates for
naloxone distribution. These relate to process utility. For example,
in Wales the national take-home program offers all new clients
tests for HIV or hepatitis B or C virus and many are trained in ﬁrst
aid [29]. Programs may increase the number of support services
available to users and may also lead to the spread of information
from trained users to nontrained users [29]. Third, the model
demonstrates cost-effectiveness in a general population of heroin
users; nevertheless, rates of overdose and effectiveness of take-
home naloxone programs are likely to vary signiﬁcantly between
risk groups. For example, rates are likely to be higher in those with
reduced tolerance (recently released from prison or hospital or
recently completed detoxiﬁcation) or using other sedating drugs
(e.g., benzodiazepines) [23,47,48]. Finally, the model base case does
not include societal costs. The topic of broader societal impact has
substantial ethical and political implications because it relates to
the positive and negative impact a heroin user can have on society.
Although we assessed the impact of adopting a societal perspec-
tive in a scenario analysis using data from previously published
models, further research is required in this area to accurately
represent the impact a take-home naloxone program would have
on society as a whole.
Conclusions
Our evaluation suggests that the distribution of take-home
naloxone decreased overdose deaths by about 6.6% and was
cost-effective with an incremental cost per QALY gained well
below a £20,000 willingness-to-pay threshold set by UK decision
makers. The model code has been made available to aid future
research. Further study is warranted on the impact of different
formulations of take-home naloxone, such as intranasal, and the
impact take-home naloxone has on the wider society.
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